Results
1 -
10 of
10A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours, Investigational New Drugs LTB4 receptor antagonists, Novel Inhibitors of Leukotrienes The Discovery of LY293111, a Novel, Potent and Orally Active Leukotriene B4 Receptor Antagonist of the Biphenylphenol Class, Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury 2 Leukotriene B4 Rezeptor 2 (BLT2) ? ein spezifischer Marker und Promoter in der Pankreaskarzinogenese?, Chirurgisches Forum 2007 Leukotriene B4 Rezeptoren sind beim duktalen Pankreaskarzinom ??berexprimiert und stellen ein neues wertvolles Therapietarget dar, Chirurgisches Forum 2004 Effects of leukotriene B4 receptor antagonist, LY293111Na, on antigen-induced bronchial hyperresponsiveness and leukocyte infiltration in sensitized guinea pigs, Inflammation Research Pharmacologic actions of the second generation leukotriene B4 receptor antagonist LY293111: in vivo pulmonary studies, Naunyn-Schmiedeberg's Archives of Pharmacology Inhibition of antigen-induced arthritis in guinea pigs by a selective LTB4 receptor antagonist LY293111Na, Inflammation Research Molecular targeting therapy for pancreatic cancer, Cancer Chemotherapy and Pharmacology